About Us

As a Swiss pharmaceutical company headquartered in Zurich, we develop, manufacture and internationally market well-proven and innovative pharmaceuticals in novel drug delivery forms.

We are a leader in advanced drug delivery technologies with a focus on modified release oral forms, and oral dispersible forms, for which we also hold patents.

With a clear focus on selected markets in the Middle East, Africa, the CIS Region, and Latin America, we are operating in some of the most dynamic countries of the world. Our in-depth knowledge of our markets enables us to adapt to local needs, however challenging.

We make and provide quality medicines having patients in mind. We are dynamic and open-minded – we seize opportunities and stay strong, even if it gets difficult.

That’s how we really make a difference. And that is the spirit we bring to all our fields of business.

Key Figures

  • Group sales*

    €279m

    As of December 31, 2016

  • Annual Growth

    +13%

    As of December 31, 2016

  • Employees

    >1,900

    As of July 3, 2017

  • Manufacturing sites

    5

    Switzerland (3), Ukraine and Estonia

  • Regional offices

    4

    Kiev, Dubai, Panama and Moscow

  • Sales offices

    4

    Johannesburg, Abidjan, Cairo and Almaty

*Acino International AG and Acino Pharma AG divested Acino’s transdermal patch and implant business including the manufacturing site in Miesbach, Germany, to Luye Pharma Group Ltd. on November 30, 2016. Group sales exclude net results from discontinued business.